Longbio Pharma

This early-stage study is checking the safety and how the body processes a new injection called LP-003 in teenagers aged 12 to 18 who have allergic diseases like asthma, eczema, or hay fever. It's a small, open-label trial at one center, meaning everyone gets the drug and researc…

This study is testing an investigational injection called LP-005 in adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease where the immune system attacks and destroys red blood cells. Researchers will measure if the treatment reduces blood cell destruction, …

This study is testing whether an investigational injection called LP-003 can reduce symptoms in adults with moderate-to-severe seasonal allergies (hay fever) that aren't well controlled by standard allergy medicines. It's a large, late-stage trial comparing the injection to a pla…

This is a very early, first-in-human study to check the safety and basic effects of a single dose of a new drug called LP-003. It involves 12 healthy adults and will measure how their bodies react to and process the drug. The goal is to gather initial safety data to see if LP-003…